GENELUX CORP (GNLX) Stock Price, Quote, News and Overview
NASDAQ:GNLX - Nasdaq - US36870H1032 - Common Stock - Currency: USD
GNLX Quote, Performance and Key Statistics
GENELUX CORP
NASDAQ:GNLX (2/5/2025, 2:52:47 PM)
4.24
+0.34 (+8.72%)
The current stock price of GNLX is 4.24 USD. In the past month the price increased by 53.54%. In the past year, price decreased by -56.38%.
GNLX Latest News, Press Releases and Analysis
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Genelux Corporation Announces New Chief Financial Officer
Genelux Corporation Announces New Chief Financial Officer
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today...
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today...
GNLX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.97 | 339.26B | ||
| AMGN | AMGEN INC | 15.49 | 164.98B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 961.82 | 126.33B | ||
| GILD | GILEAD SCIENCES INC | 22.61 | 124.81B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.76 | 79.02B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.11B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.56B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.35B | ||
| NTRA | NATERA INC | N/A | 23.34B | ||
| BIIB | BIOGEN INC | 8.95 | 21.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.62 | 15.87B |
Related stock screener links
About GNLX
Company Profile
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 23 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Company Info
GENELUX CORP
2625 Townsgate Road, Suite 230
Westlake Village CALIFORNIA US
Employees: 24
Company Website: https://genelux.com/
Investor Relations: https://www.genelux.com/investors/
Phone: 18052679889
GNLX FAQ
What is the stock price of GNLX?
The current stock price of GNLX is 4.24 USD.
What is the symbol for GENELUX CORP stock?
The exchange symbol of GENELUX CORP is GNLX and it is listed on the Nasdaq exchange.
On which exchange is GNLX stock listed?
GNLX stock is listed on the Nasdaq exchange.
Is GNLX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for GNLX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of GNLX.
Does GNLX stock pay dividends?
GNLX does not pay a dividend.
What is the Price/Earnings (PE) ratio of GNLX?
GNLX does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.95).
What is the Short Interest ratio of GNLX stock?
The outstanding short interest for GNLX is 5.7% of its float.
GNLX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to GNLX. When comparing the yearly performance of all stocks, GNLX is a bad performer in the overall market: 80.07% of all stocks are doing better.
GNLX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GNLX. No worries on liquidiy or solvency for GNLX as it has an excellent financial health rating, but there are worries on the profitability.
GNLX Financial Highlights
Over the last trailing twelve months GNLX reported a non-GAAP Earnings per Share(EPS) of -0.95. The EPS increased by -451.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.74% | ||
| ROE | -70.45% | ||
| Debt/Equity | 0 |
GNLX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to GNLX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 25.4% and a revenue growth -97.75% for GNLX